Processa Pharmaceuticals files prospectus supplement to sell up to $5.2 million shares of common stock

Processa Pharmaceuticals, Inc.

On July 25, 2025, Processa filed a prospectus supplement to its Form S-3 (Registration No. 333-279588) for an equity distribution agreement with A.G.P./Alliance Global Partners.
The supplement permits the sale of $5,239,073 shares of common stock, with $1,546,338 shares already sold in the prior 12 months.
As of the prospectus supplement date, $3,692,735 shares remain available for sale under the agreement.
The offering is conducted via an at-the-market equity distribution agreement with A.G.P./Alliance Global Partners.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.